Michelle Cummins

Dr Michelle Cummins is a researcher specializing in oncology and clinical trials, with a focus on immuno-oncology, cancer biomarkers, and genomic profiling. Her work spans multiple cancer types including colorectal, endometrial, lung, and mesothelioma, with a strong emphasis on translational research and drug development. She collaborates extensively with groups like the Australasian Gastro-Intestinal Trials Group (AGITG) and ANZGOG, contributing to Phase II and III clinical trials evaluating novel therapies such as durvalumab, tremelimumab, and bevacizumab. Key areas of interest include biomarker discovery (e.g., PD-L1, VEGF, and cell-free DNA), molecular mechanisms of cancer response, and the application of genomic profiling in personalized treatment strategies.

Her research also extends to signal transduction pathways in epithelial cells, particularly involving G-protein coupled receptors and calcium signaling mechanisms. Dr Cummins has been involved in landmark studies such as the MAX trial (colorectal cancer therapy), the PHAEDRA trial (endometrial carcinoma immunotherapy), and the ASPiRATION cohort study (lung cancer genomics). Her recent work explores the coupling of tumor and peripheral blood biomarkers in chemoimmunotherapy, reflecting her commitment to advancing precision medicine in oncology.

Dr Cummins' contributions include over 20 peer-reviewed publications, with a focus on high-impact journals in oncology, immunotherapy, and clinical research. Her work bridges basic science and clinical application, aiming to improve patient outcomes through evidence-based interventions and innovative trial designs.